ASCO 2015 Highlights

Addition of Obinutuzumab or Rituximab to Chlorambucil in Treatment-Naive Patients with CLL: Updated Survival Analysis from the CLL11 Study

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent

Impact of High-Risk Prognostic Parameters on Ibrutinib/Bendamustine/Rituximab versus Bendamustine/Rituximab Treatment Outcomes in Patients with Relapsed CLL/SLL: Results from the HELIOS Trial

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent

Health-Related Quality-of-Life Assessment of Obinutuzumab plus Bendamustine versus Bendamustine in Patients with Rituximab-Refractory Indolent NHL: Results of the GADOLIN Study

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent

Effect of Ibrutinib versus Temsirolimus Treatment on Lymphoma Symptoms in Patients with Previously Treated Mantle-Cell Lymphoma (MCL): Results of the RAY (MCL3001) Study

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent

Management of Adverse Events in the HELIOS Trial in Patients with Previously Treated CLL/SLL

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent

Abexinostat in Patients with NHL and CLL: Results of an Ongoing Phase 2 Study

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent

Venetoclax (ABT-199/GDC-0199) Monotherapy in Patients with Relapsed/Refractory NHL

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent

Venetoclax (ABT-199/GDC-0199) plus Bendamustine/Rituximab in Relapsed/Refractory NHL: Results of a Dose-Escalation Study

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent

Obinutuzumab plus Ibrutinib as Induction and Maintenance Therapy After Bendamustine Debulking in Patients with CLL: Interim Results of a Phase 2 CLL2-BIG Trial

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent

Ibrutinib versus Chlorambucil in Patients >65 Years with Treatment-Naïve CLL/SLL: Results from the Phase 3 RESONATE-2 Study

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent

Page 180 of 329